Synaptogenix Partners With LSU Health New Orleans To Study PUFA Analogs To Treat Spinal Cord Injury
2024-07-14
1049
(fxcue news) - Biopharmaceutical company Synaptogenix, Inc. (SNPX) announced Thursday a new collaboration agreement with LSU Health New Orleans' Neuroscience Center of Excellence for pre-clinical testing of the Company's polyunsaturated fatty acid (PUFA) analogs as a treatment for spinal cord injury (SCI).
The Company also announced that the US Patent and Trademark Office (USPTO) recently issued US Patent No. 12,016,837 titled 'Halogenated Esters of Cyclopropanated Unsaturated Fatty Acids for Use in the Treatment of Neurodegenerative Diseases,' covering its family of analogs. The studies will compare the analogs with Bryostatin in SCI.
Synaptogenix holds exclusive rights to its PUFA analogs pursuant to a licensing agreement with Cognitive Research Enterprises, Inc. (CRE), formerly known as the Blanchette Rockefeller Neurosciences Institute.
Sign In via X
Google
Sign In via Google
This page link:http://www.fxcue.com/32469.html
Tips:This page came from Internet, which is not standing for FXCUE opinions of this website.
Statement:Contact us if the content violates the law or your rights